CLAIMS

1. Use of a compound of formula (I)



Formula (I)

in the manufacture of a medicament for the treatment of a cancer, wherein said cancer is treated by modulating an immune response comprising a reactivation of the immune system in the tumor;

wherein said medicament is to be optionally used in combination with one or more chemotherapy agents and / or radiotherapy and / or targeted therapy;

wherein in compounds of the formula (I)

$(R^1)_n$ represents one, two or three optional substituents on the phenyl ring, wherein said substituents are independently selected from (C_{1-3})alkyl, (C_{1-3})alkoxy, -S-(C_{1-3})alkyl, halogen, (C_{1-3})fluoroalkyl, (C_{1-3})fluoroalkoxy, cyano, hydroxy, nitro, -CO-O-(C_{1-3})alkyl, -N$R^{N7}R^{N8}$ wherein R^{N7} and R^{N8} independently represent hydrogen or (C_{1-4})alkyl, or R^{N7} and R^{N8} together with the nitrogen to which they are attached form a 4- to 6-membered carbocyclic ring;

R^3 represents hydrogen, methyl or trifluoromethyl;

R^{4a} and R^{4b} independently represent hydrogen, methyl, or R^{4a} and R^{4b} together with the carbon atom to which they are attached represent a cycloprop-1,1-diyl group;

R^{5a} and R^{5b} independently represent hydrogen, methyl, or R^{5a} and R^{5b} together with the carbon atom to which they are attached represent a cycloprop-1,1-diyl group;

Ar^1 represents

- phenyl, or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl independently is mono-, di- or tri-substituted, wherein the substituents are independently selected from
  - (C_{1-6})alkyl;
  - (C_{1-4})alkoxy;
  - (C_{1-3})fluoroalkyl, wherein said (C_{1-3})fluoroalkyl is optionally substituted with hydroxy;
  - (C_{1-3})fluoroalkoxy;
  - halogen;
  - cyano;
  - (C_{3-6})cycloalkyl, wherein said (C_{3-6})cycloalkyl is unsubstituted or mono-substituted with amino;

- (C_{4-6})cycloalkyl containing a ring oxygen atom, wherein said (C_{4-6})cycloalkyl containing a ring oxygen atom is unsubstituted or mono-substituted with hydroxy;
- (C_{3-6})cycloalkyl-oxy;
- hydroxy;
- -$\mathbf{X^1}$-CO-$\mathbf{R^{O1}}$, wherein
  - $\mathbf{X^1}$ represents a direct bond, (C_{1-3})alkylene, -O-(C_{1-3})alkylene-*, -NH-(C_{1-3})alkylene-*, -S-CH_2-*, -CF_2-, –CH=CH-, –CH≡CH-, -NH-CO-*, -CO-, or (C_{3-5})cycloalkylene; wherein the asterisks indicate the bond that is linked to the -CO-$\mathbf{R^{O1}}$ group; and
  - $\mathbf{R^{O1}}$ represents
    - -OH;
    - -O-(C_{1-4})alkyl;
    - -NH-SO_2-$\mathbf{R^{S3}}$ wherein $\mathbf{R^{S3}}$ represents (C_{1-4})alkyl, (C_{3-6})cycloalkyl wherein the (C_{3-6})cycloalkyl optionally contains a ring oxygen atom, (C_{3-6})cycloalkyl-(C_{1-3})alkylene wherein the (C_{3-6})cycloalkyl optionally contains a ring oxygen atom, (C_{1-3})fluoroalkyl, or -NH_2;
    - -O-CH_2-CO-$\mathbf{R^{O4}}$, wherein $\mathbf{R^{O4}}$ represents hydroxy, or (C_{1-4})alkoxy, or -N[(C_{1-4})alkyl]$_2$;
    - -O-CH_2-O-CO-$\mathbf{R^{O5}}$, wherein $\mathbf{R^{O5}}$ represents (C_{1-4})alkyl or (C_{1-4})alkoxy;
    - -O-CH_2-CH_2-N[(C_{1-4})alkyl]$_2$; or
    - (5-methyl-2-oxo-[1,3]dioxol-4-yl)-methyloxy-;
- -CO-CH_2-OH;
- ;
- 2-hydroxy-3,4-dioxo-cyclobut-1-enyl;
- hydroxy-(C_{1-4})alkyl;
- dihydroxy-(C_{2-4})alkyl;
- hydroxy-(C_{2-4})alkoxy;
- (C_{1-4})alkoxy-(C_{2-4})alkoxy;
- -$(CH_2)_r$-CO-N$\mathbf{R^{N3}R^{N4}}$ wherein **r** represents the integer 0 or 1; and wherein $\mathbf{R^{N3}}$ and $\mathbf{R^{N4}}$ independently represent hydrogen, (C_{1-4})alkyl, hydroxy-(C_{2-4})alkyl, (C_{1-3})alkoxy-(C_{2-4})alkyl, or hydroxy;
- -$\mathbf{X^2}$-N$\mathbf{R^{N1}R^{N2}}$, wherein $\mathbf{X^2}$ represents -$(CH_2)_m$-, wherein **m** represents the integer 0 or 1; or $\mathbf{X^2}$ represents -O-CH_2-CH_2-*,wherein the asterisk indicates the bond that is linked to the -N$\mathbf{R^{N1}R^{N2}}$ group; and wherein

- $\mathbf{R^{N1}}$ and $\mathbf{R^{N2}}$ independently represent hydrogen, (C_{1-4})alkyl, (C_{1-4})alkoxy-(C_{2-4})alkyl, (C_{3-6})cycloalkyl, or (C_{2-3})fluoroalkyl;
- or $\mathbf{R^{N1}}$ independently represents hydrogen or (C_{1-4})alkyl, and $\mathbf{R^{N2}}$ independently represents –CO-H, –CO-(C_{1-3})alkyl, –CO-(C_{1-3})alkylene-OH, or –CO-O-(C_{1-3})alkyl;
- or $\mathbf{R^{N1}}$ and $\mathbf{R^{N2}}$ together with the nitrogen to which they are attached form a 4-, 5- or 6-membered saturated ring optionally containing one ring oxygen or ring sulfur atom, wherein said ring is unsubstituted, or mono-substituted with oxo on a ring carbon atom, or disubstituted with oxo on a ring sulfur atom;

- -NH-CO-N$\mathbf{R^{N5}R^{N6}}$ wherein $\mathbf{R^{N5}}$ and $\mathbf{R^{N6}}$ independently represent hydrogen or (C_{1-4})alkyl;
- -SO_2-$\mathbf{R^{S1}}$ wherein $\mathbf{R^{S1}}$ represents hydroxy, (C_{1-4})alkyl, or -N$\mathbf{R^{N7}R^{N8}}$ wherein $\mathbf{R^{N7}}$ and $\mathbf{R^{N8}}$ independently represent hydrogen or (C_{1-3})alkyl;
- -S-$\mathbf{R^{S2}}$ wherein $\mathbf{R^{S2}}$ represents (C_{1-4})alkyl, or (C_{3-6})cycloalkyl optionally containing one ring oxygen atom;
- -$(CH_2)_q$-**HET^1**, wherein **q** represents the integer 0, 1 or 2; and wherein **HET^1** represents 5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl, 3-oxo-2,3-dihydro-[1,2,4]oxadiazol-5-yl, or 5-thioxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl;
- -$(CH_2)_p$-**HET**, wherein **p** represents the integer 0 or 1; and wherein **HET** represents a 5- or 6-membered heteroaryl, wherein said 5- or 6-membered heteroaryl is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C_{1-4})alkyl, (C_{1-4})alkoxy, -COOH, hydroxy, hydroxy-(C_{1-3})alkyl, (C_{3-5})cycloalkyl optionally containing one ring oxygen atom, or -N$\mathbf{R^{N9}R^{N10}}$ wherein $\mathbf{R^{N9}}$ and $\mathbf{R^{N10}}$ independently represent hydrogen, (C_{1-3})alkyl, or hydroxy-(C_{2-4})alkyl;

- or **Ar^1** represents 8- to 10-membered bicyclic heteroaryl; wherein said 8- to 10-membered bicyclic heteroaryl independently is unsubstituted, mono-, or di-substituted, wherein the substituents are independently selected from (C_{1-4})alkyl; (C_{1-4})alkoxy; (C_{1-3})fluoroalkyl; (C_{1-3})fluoroalkoxy; halogen; cyano; hydroxy, or -(C_{0-3})alkylene-COO$\mathbf{R^{O2}}$ wherein $\mathbf{R^{O2}}$ represents hydrogen or (C_{1-4})alkyl;
- or **Ar^1** represents a group of the structure (Ar-III):



(Ar-III)

wherein ring (B) represents a non-aromatic 5- or 6-membered ring fused to the phenyl group, wherein ring (B) comprises one or two heteroatoms independently selected from nitrogen and oxygen; wherein said ring (B) independently is unsubstituted, mono-, or di-substituted, wherein the substituents are independently selected from oxo, (C_{1-6})alkyl and -(C_{0-3})alkylene-COO$\mathbf{R^{O3}}$ wherein $\mathbf{R^{O3}}$ represents hydrogen or (C_{1-3})alkyl;

or a pharmaceutically acceptable salt thereof.

2. Use according to claim 1, wherein said compound is a compound of formula (II)



Formula (II)

wherein

$(R^1)_n$ represents one, two or three optional substituents on the phenyl ring, wherein said substituents are independently selected from (C_{1-3})alkyl, (C_{1-3})alkoxy, -S-(C_{1-3})alkyl, halogen, (C_{1-3})fluoroalkyl, (C_{1-3})fluoroalkoxy, cyano, hydroxy, nitro, -CO-O-(C_{1-3})alkyl, -N$R^{N7}R^{N8}$ wherein R^{N7} and R^{N8} independently represent hydrogen or (C_{1-4})alkyl, or R^{N7} and R^{N8} together with the nitrogen to which they are attached form a 4- to 6-membered carbocyclic ring;

R^3 represents hydrogen, or methyl;

Ar^1 represents

- a phenyl group of the structure (Ar-I):



(Ar-I)

wherein

- R^p represents
  - (C_{4-6})cycloalkyl containing a ring oxygen atom, wherein said (C_{4-6})cycloalkyl containing a ring oxygen atom is unsubstituted or mono-substituted with hydroxy;
  - hydroxy;
  - -X^1-CO-R^{O1}, wherein
    - X^1 represents a direct bond, (C_{1-3})alkylene, -O-(C_{1-3})alkylene-*, -NH-(C_{1-3})alkylene-*, -CH=CH-, -NH-CO-*, or (C_{3-5})cycloalkylene; wherein the asterisks indicate the bond that is linked to the -CO-R^{O1} group; and
    - R^{O1} represents
      - -OH;

- -O-(C_{1-4})alkyl;
- -NH-SO_2-$\mathbf{R^{S3}}$ wherein $\mathbf{R^{S3}}$ represents (C_{1-4})alkyl, (C_{3-6})cycloalkyl wherein the (C_{3-6})cycloalkyl optionally contains a ring oxygen atom, (C_{3-6})cycloalkyl-(C_{1-3})alkylene wherein the (C_{3-6})cycloalkyl optionally contains a ring oxygen atom, (C_{1-3})fluoroalkyl, or -NH_2;
- -O-CH_2-CO-$\mathbf{R^{O4}}$, wherein $\mathbf{R^{O4}}$ represents hydroxy, or (C_{1-4})alkoxy, or -N[(C_{1-4})alkyl]$_2$;
- -O-CH_2-O-CO-$\mathbf{R^{O5}}$, wherein $\mathbf{R^{O5}}$ represents (C_{1-4})alkyl or (C_{1-4})alkoxy;
- -O-CH_2-CH_2-N[(C_{1-4})alkyl]$_2$; or
- (5-methyl-2-oxo-[1,3]dioxol-4-yl)-methyloxy-;

- ;
- 2-hydroxy-3,4-dioxo-cyclobut-1-enyl;
- hydroxy-(C_{1-4})alkyl;
- hydroxy-(C_{2-4})alkoxy;
- -(CH_2)$_r$-CO-N$\mathbf{R^{N3}R^{N4}}$ wherein **r** represents the integer 0 or 1; and wherein $\mathbf{R^{N3}}$ and $\mathbf{R^{N4}}$ independently represent hydrogen, (C_{1-4})alkyl, hydroxy-(C_{2-4})alkyl, (C_{1-3})alkoxy-(C_{2-4})alkyl, or hydroxy;
- -N$\mathbf{R^{N1}R^{N2}}$, wherein $\mathbf{R^{N1}}$ independently represents hydrogen or (C_{1-4})alkyl, and $\mathbf{R^{N2}}$ independently represents –CO-H, –CO-(C_{1-3})alkyl, or –CO-(C_{1-3})alkylene-OH;
- -NH-CO-N$\mathbf{R^{N5}R^{N6}}$ wherein $\mathbf{R^{N5}}$ and $\mathbf{R^{N6}}$ independently represent hydrogen or (C_{1-4})alkyl;
- -SO_2-$\mathbf{R^{S1}}$ wherein $\mathbf{R^{S1}}$ represents (C_{1-4})alkyl, or -N$\mathbf{R^{N7}R^{N8}}$ wherein $\mathbf{R^{N7}}$ and $\mathbf{R^{N8}}$ independently represent hydrogen or (C_{1-3})alkyl;
- -(CH_2)$_q$-$\mathbf{HET^1}$, wherein **q** represents the integer 0, 1 or 2; and wherein $\mathbf{HET^1}$ represents 5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl, 3-oxo-2,3-dihydro-[1,2,4]oxadiazol-5-yl, or 5-thioxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl;
- -(CH_2)$_p$-**HET**, wherein **p** represents the integer 0 or 1; and wherein **HET** represents a 5-membered heteroaryl, wherein said 5-membered heteroaryl is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C_{1-4})alkyl, (C_{1-4})alkoxy, -COOH, hydroxy, hydroxy-(C_{1-3})alkyl, (C_{3-5})cycloalkyl optionally containing one ring oxygen atom, or -N$\mathbf{R^{N9}R^{N10}}$ wherein $\mathbf{R^{N9}}$ and $\mathbf{R^{N10}}$ independently represent hydrogen, (C_{1-3})alkyl, or hydroxy-(C_{2-4})alkyl;

- $\mathbf{R^{m1}}$ represents
  - hydrogen;
  - (C_{1-6})alkyl;
  - (C_{1-4})alkoxy;

- (C_{1-3})fluoroalkyl;
- (C_{1-3})fluoroalkoxy;
- halogen;
- (C_{3-6})cycloalkyl;
- (C_{3-6})cycloalkyl-oxy;
- hydroxy;
- hydroxy-(C_{2-4})alkoxy;
- -$\mathbf{X^2}$-N$\mathbf{R^{N1}R^{N2}}$, wherein $\mathbf{X^2}$ represents a direkt bond; or $\mathbf{X^2}$ represents -O-CH_2-CH_2-*, wherein the asterisk indicates the bond that is linked to the -N$\mathbf{R^{N1}R^{N2}}$ group; and wherein $\mathbf{R^{N1}}$ and $\mathbf{R^{N2}}$ independently represent hydrogen, (C_{1-4})alkyl, or (C_{3-6})cycloalkyl;
- -S-$\mathbf{R^{S2}}$ wherein $\mathbf{R^{S2}}$ represents (C_{1-4})alkyl, or (C_{3-6})cycloalkyl optionally containing one ring oxygen atom;

- $\mathbf{R^{m2}}$ represents hydrogen, methyl, fluoro, or chloro; and
- $\mathbf{R^{o1}}$ represents hydrogen; or, in case $\mathbf{R^{m2}}$ represents hydrogen, $\mathbf{R^{o1}}$ represents hydrogen or fluoro;

- or $\mathbf{Ar^1}$ represents a 5-membered heteroaryl group of the structure (Ar-II):



(Ar-II)

wherein

- **Y** represents C$\mathbf{R^8}$ wherein $\mathbf{R^8}$ represents hydrogen or halogen; or **Y** represents N;
- $\mathbf{R^7}$ represents
  - (C_{4-6})cycloalkyl containing a ring oxygen atom, wherein said (C_{4-6})cycloalkyl containing a ring oxygen atom is unsubstituted or mono-substituted with hydroxy;
  - -$\mathbf{X^1}$-CO-$\mathbf{R^{O1}}$, wherein
    - $\mathbf{X^1}$ represents a direct bond, (C_{1-3})alkylene, -O-(C_{1-3})alkylene-*, -NH-(C_{1-3})alkylene-*, –CH=CH-, -NH-CO-*, or (C_{3-5})cycloalkylene; wherein the asterisks indicate the bond that is linked to the -CO-$\mathbf{R^{O1}}$ group; and
    - $\mathbf{R^{O1}}$ represents
      - -OH;
      - -O-(C_{1-4})alkyl;
      - -NH-SO_2-$\mathbf{R^{S3}}$ wherein $\mathbf{R^{S3}}$ represents (C_{1-4})alkyl, (C_{3-6})cycloalkyl wherein the (C_{3-6})cycloalkyl optionally contains a ring oxygen atom, (C_{3-6})cycloalkyl-(C_{1-3})alkylene

wherein the (C_{3-6})cycloalkyl optionally contains a ring oxygen atom, (C_{1-3})fluoroalkyl, or -NH_2;

- -O-CH_2-CO-$\mathbf{R^{O4}}$, wherein $\mathbf{R^{O4}}$ represents hydroxy, or (C_{1-4})alkoxy, or -N[(C_{1-4})alkyl]$_2$;
- -O-CH_2-O-CO-$\mathbf{R^{O5}}$, wherein $\mathbf{R^{O5}}$ represents (C_{1-4})alkyl or (C_{1-4})alkoxy;
- -O-CH_2-CH_2-N[(C_{1-4})alkyl]$_2$; or
- (5-methyl-2-oxo-[1,3]dioxol-4-yl)-methyloxy-;

- ;
- 2-hydroxy-3,4-dioxo-cyclobut-1-enyl;
- hydroxy-(C_{1-4})alkyl;
- hydroxy-(C_{2-4})alkoxy;
- -(CH_2)$_r$-CO-N$\mathbf{R^{N3}R^{N4}}$ wherein **r** represents the integer 0 or 1; and wherein $\mathbf{R^{N3}}$ and $\mathbf{R^{N4}}$ independently represent hydrogen, (C_{1-4})alkyl, hydroxy-(C_{2-4})alkyl, (C_{1-3})alkoxy-(C_{2-4})alkyl, or hydroxy;
- -N$\mathbf{R^{N1}R^{N2}}$, wherein $\mathbf{R^{N1}}$ independently represents hydrogen or (C_{1-4})alkyl, and $\mathbf{R^{N2}}$ independently represents –CO-H, –CO-(C_{1-3})alkyl, or –CO-(C_{1-3})alkylene-OH;
- -NH-CO-N$\mathbf{R^{N5}R^{N6}}$ wherein $\mathbf{R^{N5}}$ and $\mathbf{R^{N6}}$ independently represent hydrogen or (C_{1-4})alkyl;
- -SO_2-$\mathbf{R^{S1}}$ wherein $\mathbf{R^{S1}}$ represents (C_{1-4})alkyl, or -N$\mathbf{R^{N7}R^{N8}}$ wherein $\mathbf{R^{N7}}$ and $\mathbf{R^{N8}}$ independently represent hydrogen or (C_{1-3})alkyl;
- -(CH_2)$_q$-$\mathbf{HET^1}$, wherein **q** represents the integer 0, 1 or 2; and wherein $\mathbf{HET^1}$ represents 5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl, 3-oxo-2,3-dihydro-[1,2,4]oxadiazol-5-yl, or 5-thioxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl;
- -(CH_2)$_p$-**HET**, wherein **p** represents the integer 0 or 1; and wherein **HET** represents a 5-membered heteroaryl, wherein said 5-membered heteroaryl is unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from (C_{1-4})alkyl, (C_{1-4})alkoxy, -COOH, hydroxy, hydroxy-(C_{1-3})alkyl, (C_{3-5})cycloalkyl optionally containing one ring oxygen atom, or -N$\mathbf{R^{N9}R^{N10}}$ wherein $\mathbf{R^{N9}}$ and $\mathbf{R^{N10}}$ independently represent hydrogen, (C_{1-3})alkyl, or hydroxy-(C_{2-4})alkyl;

- $\mathbf{R^6}$ represents
  - (C_{1-6})alkyl;
  - (C_{1-4})alkoxy;
  - (C_{1-3})fluoroalkyl;
  - (C_{1-3})fluoroalkoxy;
  - halogen;
  - hydroxy;
  - (C_{3-6})cycloalkyl;

- (C_{3-6})cycloalkyl-oxy;
- hydroxy-(C_{2-4})alkoxy;
- -$\mathbf{X^2}$-N$\mathbf{R^{N1}R^{N2}}$, wherein $\mathbf{X^2}$ represents a direkt bond; or $\mathbf{X^2}$ represents -O-CH_2-CH_2-*, wherein the asterisk indicates the bond that is linked to the -N$\mathbf{R^{N1}R^{N2}}$ group; and wherein $\mathbf{R^{N1}}$ and $\mathbf{R^{N2}}$ independently represent hydrogen, (C_{1-4})alkyl, or (C_{3-6})cycloalkyl;;
- -S-$\mathbf{R^{S2}}$ wherein $\mathbf{R^{S2}}$ represents (C_{1-4})alkyl, or (C_{3-6})cycloalkyl optionally containing one ring oxygen atom;

- or $\mathbf{Ar^1}$ represents 8- to 10-membered bicyclic heteroaryl; wherein said 8- to 10-membered bicyclic heteroaryl independently is mono-substituted with -(C_{0-3})alkylene-COO$\mathbf{R^{O2}}$ wherein $\mathbf{R^{O2}}$ represents hydrogen or (C_{1-4})alkyl;
- or $\mathbf{Ar^1}$ represents a group of the structure (Ar-III):



(Ar-III)

which is selected from 2-oxo-2,3-dihydro-benzooxazol-6-yl, 3-methyl-2-oxo-2,3-dihydro-benzooxazol-5-yl, 1-methyl-3-oxo-2,3-dihydro-1H-indazol-6-yl, 2-oxo-1,2,3,4-tetrahydro-quinazolin-6-yl, 1-methyl-2-oxo-1,2,3,4-tetrahydro-quinazolin-6-yl, 1-oxo-1,2,3,4-tetrahydro-isoquinolin-6-yl, 1-methyl-2-oxo-1,2,3,4-tetrahydro-quinazolin-7-yl, and 1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl;

or a pharmaceutically acceptable salt thereof.

3. Use according to claim 1 or 2; wherein $\mathbf{Ar^1}$ represents a group selected from:










OH
H
N
O
O
OH
NH2
COOH
Cl
F
HN
NH





or a pharmaceutically acceptable salt thereof.

4. Use according to claim 3, wherein

$(R^1)_n$ represents one, two or three substituents on the phenyl ring, wherein said substituents are independently selected from (C_{1-3})alkyl, (C_{1-3})alkoxy, -S-(C_{1-3})alkyl, halogen, (C_{1-3})fluoroalkyl, (C_{1-3})fluoroalkoxy, cyano, hydroxy, nitro, -CO-O-(C_{1-3})alkyl, -N$R^{N7}R^{N8}$ wherein R^{N7} and R^{N8} independently represent hydrogen or (C_{1-4})alkyl, or R^{N7} and R^{N8} together with the nitrogen to which they are attached form a 4- to 6-membered carbocyclic ring;

or a pharmaceutically acceptable salt thereof.

5. A compound of formula (III)



Formula (III)

wherein in compounds of the formula (III)

$(R^1)_n$ represents one, two or three optional substituents on the phenyl ring (i.e. n represents the integer 0, 1, 2, or 3), wherein said substituents are independently selected from (C_{1-3})alkyl, (C_{1-3})alkoxy, -S-(C_{1-3})alkyl, halogen, (C_{1-3})fluoroalkyl, (C_{1-3})fluoroalkoxy, cyano, hydroxy, nitro, -CO-O-(C_{1-3})alkyl, -N$R^{N7}R^{N8}$ wherein R^{N7} and R^{N8} independently represent hydrogen or (C_{1-4})alkyl, or R^{N7} and R^{N8} together with the nitrogen to which they are attached form a 4- to 6-membered carbocyclic ring;

and Ar^1 represents

- a phenyl group of the structure (Ar-I):



(Ar-I)

wherein

- **R^{p}** represents
  - -**X^{1}**-CO-**R^{O1}**, wherein
    - **X^{1}** represents a direct bond, (C_{1-3})alkylene, -O-(C_{1-3})alkylene-*, -NH-(C_{1-3})alkylene-*, -CH=CH-, -NH-CO-*, or (C_{3-5})cycloalkylene; wherein the asterisks indicate the bond that is linked to the -CO-**R^{O1}** group; and
    - **R^{O1}** represents
      - -OH;
      - -O-(C_{1-4})alkyl;
      - -NH-SO_2-**R^{S3}** wherein **R^{S3}** represents (C_{1-4})alkyl, (C_{3-6})cycloalkyl wherein the (C_{3-6})cycloalkyl optionally contains a ring oxygen atom, (C_{3-6})cycloalkyl-(C_{1-3})alkylene wherein the (C_{3-6})cycloalkyl optionally contains a ring oxygen atom, (C_{1-3})fluoroalkyl, or -NH_2;
  - **HET^{1}**, wherein **HET^{1}** represents 5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl, or 3-oxo-2,3-dihydro-[1,2,4]oxadiazol-5-yl; or
  - **HET**, wherein **HET** represents a group selected from 1H-tetrazol-5-yl, 3-hydroxy-isoxazol-5-yl, 2-hydroxy-[1,3,4]oxadiazol-4-yl, 3-amino-isoxazol-5-yl, 2-amino-oxazol-5-yl, 5-amino-[1,3,4]thiadiazol-2-yl, 5-methylamino-[1,3,4]thiadiazol-2-yl, 5-amino-[1,2,4]oxadiazol-3-yl;
- **R^{m1}** represents
  - (C_{1-6})alkyl;
  - (C_{1-4})alkoxy;
  - (C_{1-3})fluoroalkyl;
  - (C_{1-3})fluoroalkoxy;
  - halogen;
  - (C_{3-6})cycloalkyl;
  - (C_{3-6})cycloalkyl-oxy;
  - hydroxy-(C_{2-4})alkoxy; or
  - -S-**R^{S2}** wherein **R^{S2}** represents (C_{1-4})alkyl, or (C_{3-6})cycloalkyl optionally containing one ring oxygen atom;
- **R^{m2}** represents hydrogen, methyl, fluoro, or chloro; and
- **R^{o1}** represents hydrogen;

- or **Ar¹** represents a 5-membered heteroaryl group of the structure (Ar-II):



(Ar-II)

wherein

- **Y** represents CH or N;
- **R⁷** represents
  - -**X¹**-CO-**R^O1**, wherein
    - **X¹** represents a direct bond, (C_{1-3})alkylene, -O-(C_{1-3})alkylene-*, -NH-(C_{1-3})alkylene-*,–CH=CH-, -NH-CO-*, or (C_{3-5})cycloalkylene; wherein the asterisks indicate the bond that is linked to the -CO-**R^O1** group; and
    - **R^O1** represents
      - -OH;
      - -O-(C_{1-4})alkyl;
      - -NH-SO_2-**R^S3** wherein **R^S3** represents (C_{1-4})alkyl, (C_{3-6})cycloalkyl wherein the (C_{3-6})cycloalkyl optionally contains a ring oxygen atom, (C_{3-6})cycloalkyl-(C_{1-3})alkylene wherein the (C_{3-6})cycloalkyl optionally contains a ring oxygen atom, (C_{1-3})fluoroalkyl, or -NH_2;
  - **HET¹**, wherein **HET¹** represents 5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl, or 3-oxo-2,3-dihydro-[1,2,4]oxadiazol-5-yl; or
  - **HET**, wherein **HET** represents a group selected from 1H-tetrazol-5-yl, 3-hydroxy-isoxazol-5-yl, 2-hydroxy-[1,3,4]oxadiazol-4-yl, 3-amino-isoxazol-5-yl, 2-amino-oxazol-5-yl, 5-amino-[1,3,4]thiadiazol-2-yl, 5-methylamino-[1,3,4]thiadiazol-2-yl, 5-amino-[1,2,4]oxadiazol-3-yl;
- **R⁶** represents
  - (C_{1-6})alkyl;
  - (C_{1-4})alkoxy;
  - (C_{1-3})fluoroalkyl;
  - (C_{1-3})fluoroalkoxy;
  - halogen;
  - (C_{3-6})cycloalkyl;
  - (C_{3-6})cycloalkyl-oxy;
  - hydroxy-(C_{2-4})alkoxy; or

- -S-$\mathbf{R^{S2}}$ wherein $\mathbf{R^{S2}}$ represents (C_{1-4})alkyl, or (C_{3-6})cycloalkyl optionally containing one ring oxygen atom;

or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 5; wherein $\mathbf{Ar^1}$ represents a group selected from



;



and

or a pharmaceutically acceptable salt thereof.

7. A compound according to claim 5; wherein $(R^1)_n$ represents one, two or three substituents on the phenyl ring, wherein said substituents are independently selected from (C_{1-3})alkyl, (C_{1-3})alkoxy, -S-(C_{1-3})alkyl, halogen, (C_{1-3})fluoroalkyl, (C_{1-3})fluoroalkoxy, cyano, or hydroxy;

or a pharmaceutically acceptable salt thereof.

8. A compound according to claims 5; wherein the fragment



represents a group selected from phenyl, 4-bromo-phenyl, 3-bromo-phenyl, 2-bromo-phenyl, 4-chloro-phenyl, 3-chloro-phenyl, 2-chloro-phenyl, 4-fluoro-phenyl, 3-fluoro-phenyl, 2-fluoro-phenyl, 2-methyl-phenyl, 3-methyl-phenyl, 4-methyl-phenyl, 4-hydroxy-phenyl, 4-methoxy-phenyl, 3-methoxy-phenyl, 2-methoxy-phenyl, 4-bromo-2-methyl-phenyl, 4-bromo-3-methyl-phenyl, 2,4-dimethyl-phenyl, 3,4-dimethyl-phenyl, 2,4-dichloro-phenyl, 3,4-dichloro-phenyl, 2,6-difluoro-phenyl, 4-bromo-3-chloro-phenyl, 4-bromo-2-chloro-phenyl, 2-bromo-5-chloro-phenyl, 4-bromo-3-fluoro-phenyl, 4-bromo-2-fluoro-phenyl, 4-chloro-2,6-difluoro-phenyl, 3-chloro-2,6-difluoro-phenyl, 2-chloro-3,6-difluoro-phenyl, 2,4,6-trifluoro-phenyl, 4-bromo-2,5-difluoro-phenyl, 4-bromo-2,6-difluoro-phenyl, 4-bromo-2-ethyl-phenyl, 4-bromo-5-fluoro-2-methyl-phenyl, 4-bromo-2-fluoro-5-methyl-phenyl, 3-hydroxy-4-methoxy-phenyl, 4-hydroxy-3-methoxy-phenyl, 3-chloro-4-methoxy-phenyl, 4-bromo-3-methoxy-phenyl, 3-bromo-4-methoxy-phenyl, 2-fluoro-4-methoxy-phenyl, 4-bromo-2-methoxy-phenyl, 5-bromo-2-methoxy-phenyl, 2-ethoxy-phenyl, 5-chloro-2-cyano-phenyl, 4-chloro-2-cyano-phenyl, 4-fluoro-2-cyano-phenyl, 4-chloro-2-methylamino-phenyl, 4-trifluoromethyl-phenyl, 3-trifluoromethyl-phenyl, 2-trifluoromethyl-phenyl, 2,5-dimethoxy-phenyl, 2,3-dimethoxy-phenyl, 2,4-dimethoxy-phenyl, 3,5-dimethoxy-phenyl, 3-(methoxy-carbonyl)-phenyl, 2-methoxy-5-(methylsulfanyl)-phenyl, 2-methoxy-4-(methylsulfanyl)-phenyl, 4-fluoro-2-ethoxy-phenyl, 4-bromo-2-ethoxy-phenyl, 2-ethyl-4-methoxy-phenyl, 2-methoxy-4,5-dimethyl-phenyl, 4-chloro-6-fluoro-2-methoxy-phenyl, 4-bromo-6-fluoro-2-methoxy-phenyl, 4-dimethylamino-2-fluoro-phenyl, 2-dimethylamino-4-bromo-phenyl, 4-chloro-2-nitro-phenyl, 2-fluoro-4-trifluoromethyl-phenyl, 4-bromo-2,6-dimethoxy-phenyl, 4-bromo-2-*n*-propoxy-phenyl, 4-bromo-2-trifluoromethoxy-phenyl, 4-bromo-2-(pyrrolidin-1-yl)-phenyl, 2-ethoxy-4-trifluoromethyl-phenyl, 3,4-dichloro-2-methyl-phenyl, 5-bromo-2-methylsulfanyl-phenyl, 2-fluoro-6-methoxy-phenyl, 2-methoxy-6-methyl-phenyl, 2-methoxy-4,6-dimethyl-phenyl, 4,5-difluoro-2-methoxy-phenyl, 2,6-difluoro-4-methoxy-phenyl, 4-difluoromethoxy-2-methoxy-phenyl, 4-difluoromethyl-5-fluoro-2-methoxy-phenyl, 2-methoxy-4-trifluoromethyl-phenyl, 4-difluoromethyl-2-methoxy-5-methyl-phenyl, 2-methoxy-4-trifluoromethoxy-phenyl, 2-fluoro-6-methoxy-4-trifluoromethyl-phenyl, 5-chloro-2-methoxy-4-trifluoromethyl-phenyl, and 2-difluoromethoxy-4-trifluoromethyl-phenyl;

or a pharmaceutically acceptable salt thereof.

9. A compound according to claim 6; wherein the fragment



represents a group selected from 4-bromo-phenyl, 4-chloro-phenyl, 4-methyl-phenyl, 2,4-dichloro-phenyl, 3,4-dichloro-phenyl, 2,6-difluoro-phenyl, 4-bromo-3-chloro-phenyl, 4-bromo-2-chloro-phenyl, 2-bromo-5-chloro-phenyl, 4-bromo-2-fluoro-phenyl, 4-chloro-2,6-difluoro-phenyl, 3-chloro-2,6-difluoro-phenyl, 2-chloro-3,6-difluoro-phenyl, 2,4,6-trifluoro-phenyl, 4-bromo-2,5-difluoro-phenyl, 4-bromo-2,6-difluoro-phenyl, 4-bromo-2-fluoro-5-methyl-phenyl, 4-hydroxy-3-methoxy-phenyl, 4-bromo-3-methoxy-phenyl, 2-fluoro-4-methoxy-phenyl, 4-bromo-2-methoxy-phenyl, 5-bromo-2-methoxy-phenyl, 2,5-dimethoxy-phenyl, 2,3-dimethoxy-phenyl, 2,4-dimethoxy-phenyl, 2-methoxy-4-(methylsulfanyl)-phenyl, 4-bromo-2-ethoxy-phenyl, 2-ethyl-4-methoxy-phenyl, 2-methoxy-4,5-dimethyl-phenyl, 4-chloro-6-fluoro-2-methoxy-phenyl, 4-bromo-2,6-dimethoxy-phenyl, 4-bromo-2-*n*-propoxy-phenyl, and 2-ethoxy-4-trifluoromethyl-phenyl;

or a pharmaceutically acceptable salt thereof.

10. A compound according to claim 5 selected from the group consisting of:

3-Fluoro-5-[6-(2-p-tolyl-ethylamino)-pyrimidin-4-yl]-thiophene-2-carboxylic acid;
4-{6-[2-(2-Methoxy-4-methylsulfanyl-phenyl)-ethylamino]-pyrimidin-4-yl}-2-methylsulfanyl-benzoic acid;
4-{6-[2-(2-Methoxy-4,5-dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-2-methylsulfanyl-benzoic acid;
3-Ethoxy-5-{6-[2-(2-methoxy-4-methylsulfanyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
3-Ethoxy-5-{6-[2-(2-methoxy-4,5-dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
2-Ethoxy-4-{6-[2-(2-methoxy-4,5-dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-benzoic acid;
3-(4-{6-[2-(4-Bromo-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethoxy-phenyl)-[1,2,4]oxadiazol-5(4H)-one;
3-(4-(6-((4-bromophenethyl)amino)pyrimidin-4-yl)-2-ethoxyphenyl)-[1,2,4]oxadiazol-5-ol;
4-{6-[2-(3,4-Dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-2-methylsulfanyl-benzoic acid;
4-{6-[2-(4-Bromo-2-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethoxy-benzoic acid;
[2-(4-Bromo-2,6-difluoro-phenyl)-ethyl]-{6-[3-ethoxy-4-(1H-tetrazol-5-yl)-phenyl]-pyrimidin-4-yl}-amine;
N-(4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethoxy-phenyl)-oxalamic acid;
5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-4-chloro-3-ethoxy-thiophene-2-carboxylic acid;
5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-methyl-thiophene-2-carboxylic acid;
5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethyl-thiophene-2-carboxylic acid;
5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-chloro-thiophene-2-carboxylic acid;
5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-(2-hydroxy-ethoxy)-thiophene-2-carboxylic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-methylsulfanyl-benzoic acid;

4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-isobutyl-benzoic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-difluoromethoxy-benzoic acid;
3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-propionic acid;
3-(4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethoxy-phenoxy)-propionic acid;
(E)-3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-acrylic acid;
(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-acetic acid;
(4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethoxy-phenyl)-acetic acid;
5-{6-[2-(4-Bromo-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
3-Ethoxy-5-{6-[2-(4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
3-Ethoxy-5-{6-[2-(3-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
5-[6-(2-p-Tolyl-ethylamino)-pyrimidin-4-yl]-3-trifluoromethyl-thiophene-2-carboxylic acid;
5-{6-[2-(4-Chloro-2-nitro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
5-{6-[2-(2,4-Dichloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
5-{6-[2-(3,4-Dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
5-{6-[2-(5-Bromo-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
5-{6-[2-(2,5-Dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
5-{6-[2-(2,4-Dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
5-{6-[2-(4-Chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
3-(5-{6-[2-(4-Bromo-2-ethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(4-Bromo-2-ethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(4-Chloro-2-fluoro-6-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(4-Chloro-2-fluoro-6-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(4-Bromo-2-fluoro-6-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(4-Bromo-2-fluoro-6-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(4-Bromo-2,6-dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(4-Bromo-2,6-dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(4-Bromo-2-propoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(4-Bromo-2-propoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(3-Ethoxy-5-{6-[2-(2-ethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(3-Ethoxy-5-{6-[2-(2-ethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(3-Ethoxy-5-{6-[2-(2-fluoro-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(3-Ethoxy-5-{6-[2-(2-fluoro-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(2-Bromo-5-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(2-Bromo-5-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(3-Ethoxy-5-{6-[2-(2-ethoxy-4-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(3-Ethoxy-5-{6-[2-(2-ethoxy-4-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

5-Chloro-2-(2-((6-(4-ethoxy-5-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)thiophen-2-yl)pyrimidin-4-yl)amino)ethyl)benzonitrile;

5-Chloro-2-(2-{6-[4-ethoxy-5-(5-hydroxy-[1,2,4]oxadiazol-3-yl)-thiophen-2-yl]-pyrimidin-4-ylamino}-ethyl)-benzonitrile;

2-(2-{6-[4-Ethoxy-5-(5-hydroxy-[1,2,4]oxadiazol-3-yl)-thiophen-2-yl]-pyrimidin-4-ylamino}-ethyl)-5-fluoro-benzonitrile;

2-(2-((6-(4-Ethoxy-5-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)thiophen-2-yl)pyrimidin-4-yl)amino)ethyl)-5-fluorobenzonitrile;

3-(5-{6-[2-(3-Chloro-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(3-Chloro-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(3-Ethoxy-5-{6-[2-(2-ethyl-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(3-Ethoxy-5-{6-[2-(2-ethyl-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(2-Chloro-3,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(2-Chloro-3,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(3-Ethoxy-5-{6-[2-(2,4,6-trifluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(3-Ethoxy-5-{6-[2-(2,4,6-trifluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(3-Ethoxy-5-{6-[2-(2-ethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(3-Ethoxy-5-{6-[2-(2-ethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(2,6-Difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(2,6-Difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Chloro-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Chloro-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Bromo-3-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-3-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Bromo-2,5-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-2,5-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Bromo-3-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-3-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Bromo-5-fluoro-2-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-5-fluoro-2-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Bromo-3-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-3-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Bromo-2-fluoro-5-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-2-fluoro-5-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Bromo-3-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-3-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(2,4-Dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(2,4-Dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(3-Ethoxy-5-{6-[2-(4-hydroxy-3-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(3-Ethoxy-5-{6-[2-(4-hydroxy-3-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(2,3-Dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(2,3-Dimethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(5-Bromo-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(5-Bromo-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(3,4-Dichloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(3,4-Dichloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(2,4-Dichloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(2,4-Dichloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Bromo-2-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-2-chloro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Bromo-2-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-2-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Bromo-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Bromo-2-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-2-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Bromo-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

[2-(4-Bromo-phenyl)-ethyl]-{6-[4-ethoxy-5-(1H-tetrazol-5-yl)-thiophen-2-yl]-pyrimidin-4-yl}-amine;

3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-trifluoromethyl-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-trifluoromethyl-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

2-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-4-ethoxy-thiazole-5-carboxylic acid;

2-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-4-ethyl-thiazole-5-carboxylic acid;

3-(2-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-4-ethoxy-thiazol-5-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(2-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-4-ethoxy-thiazol-5-yl)-[1,2,4]oxadiazol-5-ol;

3-(2-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-4-ethyl-thiazol-5-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(2-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-4-ethyl-thiazol-5-yl)-[1,2,4]oxadiazol-5-ol;
5-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,3,4]oxadiazol-2-ol;
5-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,3,4]-oxadiazol-2(3H)-one;
N-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carbonyl)-methanesulfonamide;
5-(6-((4-bromo-2,6-difluorophenethyl)amino)pyrimidin-4-yl)-3-ethoxy-N-sulfamoylthiophene-2-carboxamide;
3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-2-methyl-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-2-methyl-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(4-Bromo-phenyl)-ethylamino]-2-methyl-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(4-Bromo-phenyl)-ethylamino]-2-methyl-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-isopropoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-isopropoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-(2-hydroxy-ethoxy)-benzoic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-propyl-benzoic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-propoxy-benzoic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethylsulfanyl-benzoic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-cyclobutoxy-benzoic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-butoxy-benzoic acid;
4-{6-[2-(4-Bromo-2-ethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethoxy-benzoic acid;
5-{6-[2-(2,6-Difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethyl-thiophene-2-carboxylic acid;
3-Ethoxy-5-[6-(2-o-tolyl-ethylamino)-pyrimidin-4-yl]-thiophene-2-carboxylic acid;

3-Fluoro-5-{6-[2-(4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
3-Ethoxy-5-{6-[2-(4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
5-{6-[2-(2,4-Dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-trifluoromethyl-thiophene-2-carboxylic acid;
5-{6-[2-(3-Bromo-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
3-Ethoxy-5-{6-[2-(3-methoxycarbonyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
3-(5-{6-[2-(3,4-Dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(3,4-Dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
3-(3-Ethoxy-5-{6-[2-(2-fluoro-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(3-Ethoxy-5-{6-[2-(2-fluoro-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(3-Ethoxy-5-{6-[2-(3-hydroxy-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(3-Ethoxy-5-{6-[2-(3-hydroxy-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(3-Chloro-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;

3-(5-{6-[2-(3-Chloro-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

3-(5-{6-[2-(4-Dimethylamino-2-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one; and

3-(5-{6-[2-(4-Dimethylamino-2-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;

or a pharmaceutically acceptable salt thereof.

11. A compound according to claim 5 selected from the group consisting of:

5-(4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-methoxy-phenyl)-isoxazol-3-ol;

5-(4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-methoxy-phenyl)-isoxazol-3(2H)-one;

5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-methoxy-thiophene-2-carboxylic acid;

5-{6-[2-(3,4-Dichloro-2-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;

2-Cyclobutoxy-4-{6-[2-(4-difluoromethyl-5-fluoro-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-benzoic acid;

5-{6-[2-(4-Difluoromethyl-5-fluoro-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;

2-Cyclobutoxy-4-{6-[2-(2-methoxy-4,5-dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-benzoic acid;

3-Ethoxy-5-{6-[2-(2-methoxy-4,6-dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;

2-Ethoxy-4-{6-[2-(2-ethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-benzoic acid ;

4-{6-[2-(2-Ethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-2-methylsulfanyl-benzoic acid;

(2-Ethoxy-4-{6-[2-(2-ethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-phenyl)-acetic acid;

3-Ethoxy-5-{6-[2-(2-ethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;

5-{6-[2-(4-Difluoromethoxy-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;

3-Ethoxy-5-{6-[2-(2-fluoro-6-methoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;

3-(4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethoxy-phenyl)-[1,2,4]oxadiazol-5(4H)-;

3-(4-{6-[2-(4-bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethoxy-phenyl)-[1,2,4]oxadiazol-5-ol;

(4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-chloro-6-ethyl-phenyl)-acetic acid;

(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethyl-thiophen-2-yl)-acetic acid;

5-(4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethoxy-phenyl)-isoxazol-3-ol;
5-(4-(6-((4-Bromo-2,6-difluorophenethyl)amino)pyrimidin-4-yl)-2-ethoxyphenyl)isoxazol-3(2H)-one;
3-(5-{6-[2-(5-Bromo-2-methylsulfanyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5(4H)-one;
3-(5-{6-[2-(5-Bromo-2-methylsulfanyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophen-2-yl)-[1,2,4]oxadiazol-5-ol;
(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-propyl-thiophen-2-yl)-acetic acid;
(5-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-3-difluoromethoxy-thiophen-2-yl)-acetic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-butoxy-6-fluoro-benzoic acid;
3-Ethoxy-5-{6-[2-(2-methoxy-6-methyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
4-{6-[2-(2-Ethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-2-propyl-benzoic acid;
4-{6-[2-(4-Difluoromethoxy-2-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-2-methylsulfanyl-benzoic acid,
4-{6-[2-(2,6-Difluoro-4-methoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-2-methylsulfanyl-benzoic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-isobutoxy-benzoic acid;
4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-cyclopropoxy-benzoic acid;
N-(4-{6-[2-(4-Bromo-2,6-difluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-2-ethoxy-benzoyl)-methanesulfonamide;
5-{6-[2-(5-Chloro-2-methoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid;
3-Ethoxy-5-{6-[2-(2-methoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
3-Ethoxy-5-{6-[2-(2-methoxy-4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-thiophene-2-carboxylic acid;
5-{6-[2-(2-Difluoromethoxy-4-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-3-ethoxy-thiophene-2-carboxylic acid; and
3-(2-Ethoxy-4-{6-[2-(2-methoxy-4,5-dimethyl-phenyl)-ethylamino]-pyrimidin-4-yl}-phenoxy)-propionic acid;

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising, as active principle, a compound according to any one of claims 5 to 11, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

13. A compound according to any one of claims 5 to 11, or a pharmaceutically acceptable salt thereof, for use as a medicament.

14. A compound according to any one of claims 5 to 11, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of diseases selected from the group consisting of cancer; pain; endometriosis; autosomal dominant polycystic kidney disease; acute ischemic syndromes in atherosclerotic patients; pneumonia; and neurodegenerative diseases; or for use in the control of female fertility.

15. Use of a compound according to any one of claims 5 to 11, or of a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the prevention or treatment of a cancer selected from melanoma; lung

cancer; bladder cancer; renal carcinomas; gastro-intestinal cancers; endometrial cancer; ovarian cancer; cervical cancer; and neuroblastoma.

16. Use of a compound according to any one of claims 5 to 11, or of pharmaceutically acceptable salt thereof, in the preparation of a medicament for the prevention or treatment of diseases selected from the group consisting of cancer; pain; endometriosis; autosomal dominant polycystic kidney disease; acute ischemic syndromes in atherosclerotic patients; pneumonia; and neurodegenerative diseases; or for the control of female fertility.

17. Use of a compound according to any one of claims 5 to 11, or of a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a cancer, wherein said cancer is treated by modulating an immune response comprising a reactivation of the immune system in the tumor; wherein said medicament is to be optionally used in combination with one or more chemotherapy agents and / or radiotherapy and / or targeted therapy.